ArticleVirus research2026
Genetically predicted anti‑rubella virus IgG levels and dermatitis risk: A two‑sample Mendelian randomization study.
Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDermatitis is a common inflammatory skin condition with multifactorial origins. Although immune responses following vaccination or natural infection have been linked to dermatological outcomes, the causal significance of virus-specific immune markers remains unclear. This study used Mendelian randomization (MR) to investigate whether genetically predicted virus-specific IgG levels are associated with dermatitis risk.
methodsA two‑sample MR analysis was performed using genome‑wide association study (GWAS) summary statistics for IgG levels against eight common viral antigens from the Milieu Intérieur cohort and dermatitis outcomes (allergic contact dermatitis, atopic dermatitis, and other contact dermatitis) from large European cohorts. The inverse variance weighted method was used as the primary analysis method, complemented by MR‑Egger, weighted median, weighted mode, MR‑PRESSO, and leave‑one‑out sensitivity analyses.
resultsGenetically predicted anti-rubella virus IgG levels showed a suggestive association with a lower risk of allergic contact dermatitis (OR = 0.60, 95% CI: 0.41-0.88, P = 0.009). This association did not survive Bonferroni correction and should be interpreted cautiously as such. No significant associations were observed for other virus-specific IgG levels or dermatitis outcomes. Sensitivity analyses indicated no evidence of horizontal pleiotropy or influence from any single genetic variant.
conclusionThis MR study provides suggestive evidence that genetically predicted anti-rubella IgG levels may be associated with reduced allergic contact dermatitis risk. However, the findings are exploratory, do not distinguish between vaccine-induced and infection-induced immunity, and require replication and mechanistic validation. No causal associations were found for other virus-specific IgG traits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.